Message

The Japanese pharmaceutical market and new drug development sector are among the best in the world. However, even though the quality of clinical trials is high, Japan falls behind other developed countries in terms of speed and cost. This gap is causing concerns about "drug loss," where new drugs might not be developed or available in Japan.

We are the only vertical startup in Japan focused on solving this crisis by using technology to improve the clinical trial process. Our mission is to "use technology to quickly deliver new treatment options to patients."

We began by providing information to patients and physicians about clinical trials information, which are crucial for new drug approvals. Now, we are using our platform "Puzz" to streamline the entire clinical trial process. This includes efficiently conducting feasibility and site selection, centralizing the management of various trial tasks at these sites, connecting them with pharmaceutical companies for efficient project management, recruiting patients through sharing trial information, and managing patient retention. By optimizing these processes, we aim to shorten clinical trial durations and accelerate the approval of new drugs.

In the future, we plan to use technology to connect patient feedback with drug discovery, early approval of new drugs, and the development of new treatments. Along with our current clinical trial platform, we will use our patient social network, MiiLike, to create communities where patients with similar conditions can support each other. This will help them find new options from their own perspective. We also aim to use these communities to share patient feedback with pharmaceutical companies and researchers.

To achieve this vision, we are committed to continuous growth as a company. We will contribute to our stakeholders, prioritize product excellence, build a robust organization, and leverage cutting-edge technologies like generative AI and RWD/RWE. While staying grounded in the present, we will keep our focus on shaping the future we want to create.

Many diseases in the world still have unmet needs. Through our products, we aim to create a healthcare system that puts patients first, allowing them to quickly learn about and choose their treatment options. We are committed to offering new treatment choices to patients struggling with these diseases.

buzzreach is building a platform to connect pharmaceutical companies, clinical trial sites, and patients to address the challenges in Japan's pharmaceutical industry.

We call ourselves DRO, it stands for Digital Research Organization. It includes three important elements: Digital, Decentralized, and Data. These elements are essential for solving the challenges in Japan's pharmaceutical industry.

To shape the future of Japanese clinical trials through 3D transformation, we will take five key actions.

1. Support trial site operations with the Study Works platform and establish a PI network.
2. Strengthen patient identification by integrating with electronic health records.
3. Use AI technology to automatically generate necessary documents for clinical trials.
4. Facilitate decentralized clinical trials (DCT) by integrating various medical system modules with the Study Works platform.
5. Promote Patient and Public Involvement (PPI) using the patient-centered social network "MiiLike."

It's a long journey, but with the engagement and support of all stakeholders, we believe we can help address the challenges facing Japan's pharmaceutical industry.